Sun Pharmaceutical Industries announced Q1FY24 results: Gross sales at Rs 1,17,852 million, growth of 10.7% vs Q1FY23 India formulation sales at Rs 35,604 million, up 5.1% vs Q1FY23 US formulation sales at USD 471 million, up 12% vs Q1FY23 Global specialty sales at USD 232 million, up 21% vs Q1FY23 Global specialty sales accounted for 16.2% of Q1FY24 sales Emerging markets formulation sales at USD 261 million, up 6.5% vs Q1FY23. Rest of world formulation sales at USD 195 million, up 2.6% vs Q1FY23 R&D; investments at Rs 6,796 million compared to Rs 4,608 million for Q1FY23 EBITDA at Rs 33,318 million, up 15.5% vs Q1FY23. EBITDA margin for Q1 at 27.9% vs 26.8% for Q1FY23. Adjusted net profit (excluding the exceptional items) for Q1FY24 was Rs 23,454 million, up 13.8% over Q1FY23. Reported net profit for Q1FY24 was Rs 20,225 million compared to net profit of Rs 20,609 million for Q1FY23. Dilip Shanghvi, Managing Director of the company, said, “All our business continued to have growth this quarter and we are well positioned to meet our growth guidance for FY24. US has led the revenue growth in Q1 and Global Specialty has continued to increase as a share of our revenues. I am excited about the progress in our specialty pipeline and the potential for offering new treatments for patients in need.” Result PDF